Tag Archives: department

Gobbling up poison: Method for killing colon cancer

Now researchers at Thomas Jefferson University have discovered the unique biological properties inherent to colon cancer that make it a perfect candidate for immunotoxins — an antibody that won’t attach to normal cells and a toxin-delivery system that takes advantage of a fluke of biology: Colon cancer cells will gobble up poison if it’s attached to a key receptor on the cell’s surface. Indeed, the researchers demonstrated that the novel immunotoxin they created could reduce the lung metastasis in mice, which had grown out from colon cancers, by more than 80 percent with only 6 doses, in research published September 8th, 2014 in the journal Oncotarget. “These studies pave the way for effective antibody-directed therapy for metastatic disease in colorectal cancer, which currently carries a greater than 90 percent chance of mortality” says Scott Waldman, M.D., Ph.D., Chair of the Department of Pharmacology & Experimental Therapeutics and the Samuel MV Hamilton Professor at Thomas Jefferson University. Dr…

Prostate Cancer: Watchful waiting isn’t right for everyone — ScienceDaily

“We know that African American men have more aggressive prostate cancer than Caucasian men,” says Kosj Yamoah M.D., Ph.D., Chief Resident, Department of Radiation Oncology at Thomas Jefferson University. “Our study shows that African American men who are diagnosed with a low-grade cancer at first — the cancers that are sometimes watched rather than treated — are more likely to develop aggressive disease sooner than Caucasian men.” Dr. Yamoah, together with Timothy Rebbeck and colleagues from the University of Pennsylvania, looked at patients whose cancers were low to intermediate grade and who underwent surgery to remove all or part of their prostate. The surgery was important because often men are given a so called “biopsy” Gleason score of cancer severity based on 12 needle biopsies of the prostate gland…

Ovarian cancer oncogene found in ‘junk DNA’

Most of those studies have focused on the portion of the human genome that encodes protein — a fraction that accounts for just 2 percent of human DNA overall. Yet the vast majority of genomic alterations associated with cancer lie outside protein-coding genes, in what traditionally has been derided as “junk DNA.” Researchers today know that “junk DNA” is anything but — much of it is transcribed into RNA, for instance — but finding meaning in those sequences remains a challenge. Now a team led by Lin Zhang, PhD, research associate professor in the Department of Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania, has mined those sequences to identify a non-protein-coding RNA whose expression is linked to ovarian cancer. …

New genetic target for a different kind of cancer drug found

“Historically, scientists haven’t targeted the proteins in cancer cells that are involved in gene splicing,” said Zefeng Wang, PhD, associate professor in the department of pharmacology and senior author of the Cancer Cell paper. “This is a whole new ballgame in terms of gene regulation in cancer.” There are approximately 25,000 genes in the human genome — the same amount as in a fruit fly. But in humans, these genes are spliced together in different ways to create various kinds of messenger RNA to produce the many different proteins humans require…

One-two punch for brain tumors? New clinical trial opens

The experimental approach, based on U-M research, delivers two different genes directly into the brains of patients following the operation to remove the bulk of their tumors. The idea: trigger immune activity within the brain itself to kill remaining tumor cells — the ones neurosurgeons can’t take out, which make this type of tumor so dangerous. …

Ovarian Cancer: Know your body, know your risk

“There is no effective surveillance technique for the detection of early stage ovarian cancer, so the only effective way to prevent it and save lives is to identify women at risk,” said David A. Fishman, MD, Director of the Mount Sinai Ovarian Cancer Risk Assessment Program and Professor and Fellowship Director in the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Medicine at the Icahn School of Medicine at Mount Sinai. He recommends that women with a family history of ovarian and breast cancers get a formal genetic evaluation by a board-certified genetic counselor. For women who have tested positive for a BRCA mutation or are identified to be at a high risk for developing ovarian cancer, preventive surgery should be considered to remove the ovaries and fallopian tubes before ovarian cancer can develop…